Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia.

Impact of Atorvastatin Combined with Ezetimibe for the Treatment of Carotid Atherosclerosis in Patients with Coronary Heart Disease.

BACKGROUND This study aimed to investigate the impact of atorvastatin (Ato) combined with ezetimibe (Eze) for the treatment of carotid atherosclerosis in patients with coronary heart disease (CHD). METHODS One hundred and forty-eight CHD patients with carotid atherosclerosis were divided into the control (Ato alone) and combination (Ato and Eze) groups. The treatment course was 12 months; pat...

apy with 80 mg of simvastatin plus either placebo or 10 mg of ezetimibe on the average change in carotid intima–media thickness in patients with familial hypercholesterolemia. The study, called the Ezetimibe and Simvastatin in Hypercholes- terolemia Enhances Atherosclerosis Regression

n engl j med 358;14 www.nejm.org april 3, 2008 1504 In this issue of the Journal, Kastelein et al.1 report the results of a 2-year study comparing daily therapy with 80 mg of simvastatin plus either placebo or 10 mg of ezetimibe on the average change in carotid intima–media thickness in patients with familial hypercholesterolemia. The study, called the Ezetimibe and Simvastatin in Hypercholeste...

Another clinical evidence straw on the $4 billion ezetimibe camel's back.

The clinical use of ezetimibe began in 2002 when the United tates Food and Drug Administration licensed the compound for he reduction of LDL-C either alone or in combination with a statin edication. Since then, clinical use of ezetimibe has grown to levls exceeding annual sales of $4 billion, in parallel with efforts to roadly market the drug to clinicians despite the absence of definiive data ...

Atorvastatin in combination with ezetimibe and carotid atherosclerosis.

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.

BACKGROUND Patients with homozygous familial hypercholesterolemia (HoFH) have a high incidence of cardiovascular morbidity and mortality from premature atherosclerosis, and the efficacy of pharmacological therapy has been limited. We evaluated the efficacy, safety, and tolerability of ezetimibe, a novel cholesterol absorption inhibitor, in a multicenter, double-blind, randomized trial of HoFH p...